In this review, we extend our focus beyond SGLT2 inhibitors and consider several substances and conditions regarding these two prerequisites to help elucidate how these drugs may confer cardiovascular protection in situations where there is hyperfiltering states such as chronic kidney disease (CKD). The gene discussed is SLC5A2; the disease is chronic kidney disease.